The Role of Antifungals in Pediatric Critical Care Invasive Fungal Infections

Table 5

Clinical indications and dosing of echinocandins [13, 33].

Drug	Indications	Dose	Special comments
Caspofungin	Candidemia in neutropenic and nonneutropenic patients; Empiric therapy for suspected candidiasis in nonneutropenic patients with risk factors for invasive candidiasis; Candida osteoarticular infections; Second-line therapy for aspergillosis	Caspofungin: 50 mg/m2/d and 25 mg/m2/day in neonates and infants <3 months	First-line for empiric therapy of candidiasis in patients with febrile neutropenia; Consider susceptibility testing in patients with prior treatment and with Candida glabrata or Candida parapsilosis (may be resistant)
Micafungin	Same as above	1–3 mg/kg/d
Anidulafungin	Mucosal or invasive candidiasis	Age >16 years: 100–200 mg for 1 dose, then 50–100 mg/d	Not approved for pediatric use